{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:51:33Z","timestamp":1740178293776,"version":"3.37.3"},"reference-count":18,"publisher":"American Society of Hematology","issue":"6","license":[{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3,26]]},"DOI":"10.1182\/bloodadvances.2023012090","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T19:31:57Z","timestamp":1706124717000},"page":"1464-1468","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Impact of imaging frequency on progression-free survival in Alliance trials enrolling patients with follicular lymphoma"],"prefix":"10.1182","volume":"8","author":[{"given":"Sarah C.","family":"Rutherford","sequence":"first","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Weill Department of Medicine, Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Yin","sequence":"additional","affiliation":[{"name":"2Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5902-8882","authenticated-orcid":false,"given":"Levi D.","family":"Pederson","sequence":"additional","affiliation":[{"name":"2Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4229-2569","authenticated-orcid":false,"given":"Kristie A.","family":"Blum","sequence":"additional","affiliation":[{"name":"3Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Martin","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Weill Department of Medicine, Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sin-Ho","family":"Jung","sequence":"additional","affiliation":[{"name":"4Alliance Statistics and Data Management Center, Biostatistics and Bioinformatics, Duke Cancer Institute, Duke University, Durham, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Grant","sequence":"additional","affiliation":[{"name":"5Division of Hematology and Oncology, University of Vermont, Burlington, VT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cara","family":"Rosenbaum","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Weill Department of Medicine, Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce D.","family":"Cheson","sequence":"additional","affiliation":[{"name":"6Lymphoma Research Foundation, Bethesda, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy L.","family":"Bartlett","sequence":"additional","affiliation":[{"name":"7Division of Oncology, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumithra J.","family":"Mandrekar","sequence":"additional","affiliation":[{"name":"2Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Weill Department of Medicine, Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"issue":"2","key":"2024032513152254600_bib1","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bjh.14839","article-title":"Bone marrow biopsies do not impact response assessment for follicular lymphoma patients treated on clinical trials","volume":"179","author":"Rutherford","year":"2017","journal-title":"Br J Haematol"},{"issue":"8","key":"2024032513152254600_bib2","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/bloodadvances.2019001261","article-title":"Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA","volume":"4","author":"Rutherford","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"2024032513152254600_bib3","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1200\/JCO.21.02301","article-title":"Relevance of bone marrow biopsies for response assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials","volume":"41","author":"Rutherford","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"2024032513152254600_bib4","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1182\/blood-2013-07-518423","article-title":"The ASH Choosing Wisely\u00ae campaign: five hematologic tests and treatments to question","volume":"122","author":"Hicks","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2024032513152254600_bib5","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1148\/radiol.2511081300","article-title":"Whole-body PET\/CT scanning: estimation of radiation dose and cancer risk","volume":"251","author":"Huang","year":"2009","journal-title":"Radiology"},{"issue":"3","key":"2024032513152254600_bib6","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/ijc.29433","article-title":"Frequency of surveillance computed tomography in non-Hodgkin lymphoma and the risk of secondary primary malignancies: a nationwide population-based study","volume":"137","author":"Chien","year":"2015","journal-title":"Int J Cancer"},{"issue":"22","key":"2024032513152254600_bib7","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1001\/archinternmed.2009.427","article-title":"Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer","volume":"169","author":"Smith-Bindman","year":"2009","journal-title":"Arch Intern Med"},{"issue":"13","key":"2024032513152254600_bib8","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1200\/JCO.2014.58.5729","article-title":"Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission","volume":"33","author":"Huntington","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2024032513152254600_bib9","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1093\/annonc\/mdq215","article-title":"Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors","volume":"21","author":"Thompson","year":"2010","journal-title":"Ann Oncol"},{"issue":"5","key":"2024032513152254600_bib10","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.3390\/cancers15051381","article-title":"Scanxiety among adults with cancer: a scoping review to guide research and interventions","volume":"15","author":"Derry-Vick","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"31","key":"2024032513152254600_bib11","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.2014.55.7561","article-title":"Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma","volume":"32","author":"Thompson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2024032513152254600_bib12","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1182\/blood-2016-08-685073","article-title":"Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma","volume":"129","author":"Cohen","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2024032513152254600_bib13","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.3324\/haematol.2009.020115","article-title":"Surveillance investigations after high-dose therapy with stem cell rescue for recurrent follicular lymphoma have no impact on management","volume":"95","author":"Gerlinger","year":"2010","journal-title":"Haematologica"},{"issue":"21","key":"2024032513152254600_bib14","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1002\/cncr.28299","article-title":"A\u00a0phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701","volume":"119","author":"Grant","year":"2013","journal-title":"Cancer"},{"issue":"11","key":"2024032513152254600_bib15","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1093\/annonc\/mdx496","article-title":"A\u00a0phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance)","volume":"28","author":"Martin","year":"2017","journal-title":"Ann Oncol"},{"issue":"19","key":"2024032513152254600_bib16","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1002\/cncr.32289","article-title":"Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance)","volume":"125","author":"Blum","year":"2019","journal-title":"Cancer"},{"issue":"1","key":"2024032513152254600_bib17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/bjh.15768","article-title":"Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance)","volume":"185","author":"Rosenbaum","year":"2019","journal-title":"Br J Haematol"},{"issue":"21","key":"2024032513152254600_bib18","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1182\/blood-2016-06-718106","article-title":"Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103","volume":"128","author":"Ujjani","year":"2016","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/6\/1464\/2218996\/blooda_adv-2023-012090-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/6\/1464\/2218996\/blooda_adv-2023-012090-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T13:15:47Z","timestamp":1711372547000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/6\/1464\/514726\/Impact-of-imaging-frequency-on-progression-free"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,3,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012090","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"subject":[],"published":{"date-parts":[[2024,3,15]]}}}